Prognostic Application of Thoracic Aortic Calcium Scoring for Adverse Clinical Outcome Risk in Elderly Patients with Left Ventricular Hypertrophy.
- Author:
In Jeong CHO
1
;
Hyuk Jae CHANG
;
Sang Eun LEE
;
Chi Young SHIM
;
Geu Ru HONG
;
Namsik CHUNG
Author Information
- Publication Type:Original Article
- Keywords: Left ventricular hypertrophy; Vascular calcification; Prognosis
- MeSH: Aged*; Aorta, Thoracic; Calcium*; Coronary Artery Disease; Death; Echocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Hypertrophy, Left Ventricular*; Male; Myocardium; Prognosis; Stroke; Vascular Calcification; Vascular Stiffness
- From:Korean Circulation Journal 2017;47(6):918-928
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND AND OBJECTIVES: Left ventricular hypertrophy (LVH) is associated with poor cardiovascular outcomes. Heavy aortic calcification exacerbates arterial stiffness, which consequently heightens left ventricular (LV) afterload. We assessed the usefulness of aortic calcification for predicting adverse cardiovascular outcomes and to determine whether the relationship, if any, differed as a function of LVH. METHODS: The analytic sample was comprised of a total of 487 individuals 65 years of age or older. Thoracic aorta calcium score (TACS) was measured by coronary computed tomography, and patients were stratified according to the median (TACS, 446 mm3). LVH obtained from echocardiography was defined as LV mass index >115 g/m2 for men and >95 g/m2 for women. Cox regression reporting hazard ratios (HRs) with 95% confidence intervals (CIs) was performed to predict the risk for the composite study endpoint, defined as cardiac death, admission for heart failure, obstructive coronary artery disease (CAD) requiring revascularization, or stroke. RESULTS: A total of 39 composite events (8.0%) occurred during a median follow-up of 65 months (interquartile range [IQR], 17–89 months). For those with LVH, the concurrent presence of high TACS appeared to be an independent predictor (HR, 4.51; 95% CI, 1.71–11.88; p=0.002) for the composite study endpoint. Other combined LVH and TACS subgroups were not associated with significant factors for predicting the composite study endpoint (p>0.050, all). CONCLUSION: TACS provides robust predictive utility for a composite of cardiovascular events and cardiac death in persons with LVH. This finding was less pronounced in those with a relatively healthy myocardium, defined by the absence of LVH.
